Pharmaceutical Technology

SEPTEMBER 29, 2022

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Holding a presence in the cosmetic dermatology sector, Curatio’s portfolio comprises more than over 50 brands that are commercialised in India. The portfolio includes brands such as Tedibar, Atogla, Spoo, B4 Nappi and Permite.

Dermatology 147

Dermatology Cosmetics Branding Scientist 147

Pharma Marketing Network

APRIL 4, 2022

The American Academy of Dermatology (AAD) held its annual conference last weekend, and it was my privilege to be in attendance. As COVID-19 had put the brakes on the show for the past two years, that same sentiment was shared by most of the attendees and exhibitors this year.

Dermatology 52

Dermatology Cosmetics Pharma Companies Branding 52

XTalks

JUNE 17, 2024

This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the US,” said James Hartman, president of Hugel America in the news release. “As While Hugel has not disclosed the price for Letybo at this time, it is estimated that similar treatments, such as Botox Cosmetic, can range from $325 to $600.

FDA Approval 52

FDA Approval Marketing Botox Clinical Trials 52

XTalks

MAY 22, 2023

Allergan Aesthetics, an AbbVie company renowned for its development of leading aesthetics brands and products, recently announced the US Food and Drug Administration (FDA) approved their ground-breaking hyaluronic acid product, SkinVive by Juvéderm, for achieving remarkable skin smoothness.

Filler 73

Filler FDA Approval Dermatology In-Vivo 73

The Pharma Data

FEBRUARY 5, 2021

” said Dr. Sabrina Fabi , Board Certified Dermatologist and Associate Research Director at Cosmetic Laser Surgery in San Diego. American Society for Dermatologic Surgery (ASDS) consumer survey on cosmetic dermatologic procedures 2018 available at [link]. N= 3,525 total study population. About Allergan Aesthetics.

Cosmetics 52

Cosmetics Dermatology Allergies Production 52

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40